Skip to main content

Table 1 Main characteristics of the studies included in the meta-analysis

From: The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Study Author Update year Trial Phase Capecitabine arm Control arm N (Capecitabine/ Control) TNBC, N (X/Control) Median follow-up (month) Design Setting
FinXX Trial Joensuu 2017 III DX + CEX D + CEF 751/744 93/109 123.6 Addition Adjuvant
GEICAM/2003–10 Martín 2015 III ED-X EC-D 715/669 95/71 79.2 Replace Adjuvant
GAIN V. Mo 2017 III EC-PX EPC 1511/1512 213/208 74 Replace Adjuvant
US ncology 01062 O’Shaughnessy 2015 III AC-DX AC-D 1307/1304 396/384 60 Addition Adjuvant
CREATE-X Masuda 2017 III X None 443/444 139/147 43.2 Addition Adjuvant
CIBOMA 2004/01 Lluch 2019 III ED-X EC-D 448/428 448/428 87.6 Addition Neo/Adjuvant
Gepar TRIO Minckwitz 2013 III DAC-NX DAC-DAC 301/321 NA 62 Replace Neoadjuvant
CBCSG-010 Li 2019 III DX-XEC D-FEC 297/288 297/288 67 Addition Adjuvant
CALGB49907 Muss 2019 III X CMF/AC 307/326 76/78 136.8 Replace Adjuvant
  1. X capecitabine, C cyclophosphamide, M methotrexate, F 5-fluorouracil, A doxorubicin, E epirubicin, D docetaxel, BEV bevacizumab, P paclitaxel, N nab-paclitaxe, NA not available, N number